Published in
Springer Verlag, PharmacoEconomics, 10(37), p. 1195-1207, 2019
DOI: 10.1007/s40273-019-00792-7
Links
Tools
Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Journal article published in 2019 by
Sabine E. Grimm 
,
Debra Fayter,
Bram L. T. Ramaekers,
Svenja Petersohn,
Rob Riemsma,
Nigel Armstrong,
Xavier Pouwels,
Willem Witlox ,
Caro Noake,
Gillian Worthy,
Jos Kleijnen,
Manuela A. Joore
,
Debra Fayter,
Bram L. T. Ramaekers,
Svenja Petersohn,
Rob Riemsma,
Nigel Armstrong,
Xavier Pouwels,
Willem Witlox ,
Caro Noake,
Gillian Worthy,
Jos Kleijnen,
Manuela A. Joore
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 